Compendio degli studi più significativi con riferimento a proprietà, assunzione, effetti.
Kloskowski T, Szeliski K, Fekner Z, Rasmus M, Dąbrowski P, Wolska A, Siedlecka N, Adamowicz J, Drewa T, Pokrywczyńska M. Ciprofloxacin and Levofloxacin as Potential Drugs in Genitourinary Cancer Treatment-The Effect of Dose-Response on 2D and 3D Cell Cultures. Int J Mol Sci. 2021 Nov 4;22(21):11970. doi: 10.3390/ijms222111970.
Abstract. Introducing new drugs for clinical application is a very difficult, long, drawn-out, and costly process, which is why drug repositioning is increasingly gaining in importance. The aim of this study was to analyze the cytotoxic properties of ciprofloxacin and levofloxacin on bladder and prostate cell lines in vitro.
Podder V, Sadiq NM. Levofloxacin. 2021 Sep 22. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan–.
Abstract. Levofloxacin is FDA-approved for the treatment of nosocomial pneumonia, community-acquired pneumonia, acute bacterial rhinosinusitis, acute bacterial exacerbation of chronic bronchitis, acute bacterial prostatitis, acute pyelonephritis, urinary tract infection, skin or skin structure infections, prophylaxis, and treatment of plaque due to Yersinia pestis, and to reduce the incidence of disease progression of inhalational anthrax.
Deshpande D, Pasipanodya JG, Mpagama SG, Bendet P, Srivastava S, Koeuth T, Lee PS, Bhavnani SM, Ambrose PG, Thwaites G, Heysell SK, Gumbo T. Levofloxacin Pharmacokinetics/Pharmacodynamics, Dosing, Susceptibility Breakpoints, and Artificial Intelligence in the Treatment of Multidrug-resistant Tuberculosis. Clin Infect Dis. 2018 Nov 28;67(suppl_3):S293-S302. doi:
Abstract. The levofloxacin dose of 25 mg/kg or 1500 mg/day was adequate for replacement of high-dose moxifloxacin in treatment of multidrug-resistant tuberculosis.
Rafat C, Debrix I, Hertig A. Levofloxacin for the treatment of pyelonephritis. Expert Opin Pharmacother. 2013 Jun;14(9):1241-53. doi: 10.1517/14656566.2013.792805.
Abstract. Levofloxacin has achieved satisfactory bacterial eradication rates and clinical success across all available trials, similar to the antibiotic comparator.
Wrońska N, Majoral JP, Appelhans D, Bryszewska M, Lisowska K. Synergistic Effects of Anionic/Cationic Dendrimers and Levofloxacin on Antibacterial Activities. Molecules. 2019 Aug 9;24(16):2894. doi: 10.3390/molecules24162894.
Abstract. Despite the numerous studies on dendrimers for biomedical applications, the antibacterial activity of anionic phosphorus dendrimers has not been explored. In our research, we evaluated the antibacterial activity of modified polycationic and polyanionic dendrimers in combination with levofloxacin
Grillon A, Schramm F, Kleinberg M, Jehl F. Comparative Activity of Ciprofloxacin, Levofloxacin and Moxifloxacin against Klebsiella pneumoniae, Pseudomonas aeruginosa and Stenotrophomonas maltophilia Assessed by Minimum Inhibitory Concentrations and Time-Kill Studies. PLoS One. 2016 Jun 3;11(6):e0156690. doi: 10.1371/journal.pone.0156690.
Abstract. The aim of this study was to compare the in vitro susceptibility of Klebsiella pneumoniae, Pseudomonas aeruginosa and Stenotrophomonas maltophilia to three fluoroquinolones.
Sitovs A, Sartini I, Giorgi M. Levofloxacin in veterinary medicine: a literature review. Res Vet Sci. 2021 Jul;137:111-126. doi: 10.1016/j.rvsc.2021.04.031.
Abstract. Levofloxacin is also used in veterinary medicine, however its use is limited: it is completely banned for veterinary use in the EU, and used extralabel in only companion animals in the USA.
Bientinesi R, Murri R, Sacco E. Efficacy and safety of levofloxacin as a treatment for complicated urinary tract infections and pyelonephritis. Expert Opin Pharmacother. 2020 Apr;21(6):637-644. doi: 10.1080/14656566.2020.1720647.
Abstract. La levofloxacina è un antibatterico fluorochinolonico che è diventato uno dei capisaldi della terapia antibiotica delle infezioni del tratto urinario complicate e della pielonefrite sin dalla sua introduzione nel 1990 a causa del suo eccezionale profilo farmacocinetico (PK) e farmacodinamico (PD). Tuttavia, l'emergere di una diffusa resistenza ai fluorochinoloni negli ultimi dieci anni ha spinto gli investigatori a riesaminare il suo posto nel trattamento delle infezioni del tratto urinario.
Brunetti L, Lee SM, Nahass RG, Suh D, Miao B, Bucek J, Kim D, Kim OK, Suh DC. The risk of cardiac events in patients who received concomitant levofloxacin and amiodarone. Int J Infect Dis. 2019 Jan;78:50-56. doi: 10.1016/j.ijid.2018.10.017.
Abstract. Levofloxacin and amiodarone are both known to prolong the QT interval. This study was conducted to estimate the risk of cardiac events in patients receiving concomitant levofloxacin and amiodarone.
Ofloxacin 
